Efficacy and Safety of Imidapril in Patients with Essential Hypertension: A Double-Blind Comparison with Captopril

Abstract

In this 12-week, double-blind, parallel-group, comparative trial, 57 adult patients with mild-to-moderate hypertension were randomly allocated to receive imidapril or captopril, initially at a dose of 5 mg once a day and 25 mg twice daily, respectively. After 4 weeks of therapy, the dose of each drug was increased twice if diastolic blood pressure (DBP) remained ≧90 mm Hg. Both treatments effectively lowered DBP in a comparable manner. Mean changes from baseline in DBP at 12 weeks were –9.9 mm Hg for imidapril and –8.8 mm Hg for captopril (p = 0.488). Responder rates in patients receiving active treatment for at least 6 weeks were 53.9% for imidapril and 48% for captopril (p = 0.676). Both treatments were well tolerated. Adverse drug reactions were observed in 20.7% (6/29) of the imidapril group and 46.4% (13/28) of the captopril group (p < 0.05). A cough was the most frequent side effect, reported in 13.8% of the imidapril group and 35.7% of the captopril group. The results indicate that imidapril is as effective as captopril in the treatment of hypertension. Imidapril produces less adverse effects compared with captopril.

Mechanics and Function of the Pulmonary Vasculature: Implications for Pulmonary Vascular Disease and Right Ventricular Function

“…While significantly less progress has been made regarding PH-mediated histological and mechanical changes of the elastic-intrapulmonary arteries, evidence suggests that the physiological changes are similar between elastic intra and extrapulmonary arteries (53), however more research is needed to determine how PH vascular remodeling propagates through the more distal elastic arteries of the lung. The relative amounts of collagen and elastin deposited and concomitant changes in the PA F-λ curve differ somewhat between animal models.…”

A Single Nucleotide Polymorphism in the Carboxylesterase Gene Is Associated with the Responsiveness to Imidapril Medication and the Promoter Activity

“…Imidapril is as effective as captopril (13) or the calcium channel blocker nifedipine (14) for the treatment of hypertension. One study reported that the responder rates to imidapril were around 50% (13), and another that 29% of patients achieved a systolic/diastolic blood pressure (SBP/DBP) reduction to below 140/90 mmHg within an average of 26 days of treatment (15).…”

“…One study reported that the responder rates to imidapril were around 50% (13), and another that 29% of patients achieved a systolic/diastolic blood pressure (SBP/DBP) reduction to below 140/90 mmHg within an average of 26 days of treatment (15). It has been reported that the ACE I/D polymorphism may influence the ability of imidapril to prevent restenosis after percutaneous transluminal coronary angioplasty (16).…”

Safety and Efficacy of Imidapril in the Treatment of Essential Hypertension

“…Again, the most frequent adverse events were cough (13.8%) in imidapril group, 35.7% in captopril group. 41 …”